PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results for the first quarter ended March 31, 2025. We loved the firm’s strong revenue performance of $190 million,  the positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, and, important is the  NDA review remained on track for July 29, 2025, PDUFA date, the . . . This …

Alnylam Pharmaceuticals Synopsis  Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam Pharmaceuticals, said, “2025 is off to a remarkable start, having ended the first quarter with U.S . . . This …